Publisher · 9 documents · 143 figures
IQVIA Institute
143 verified figures from 9 publications by IQVIA, a research. Every figure links to the document and sentence it came from.
Data points
143
Documents
9
Indicators
89
Regions
5
Publisher type
Research
Documents used
Every publication we have taken a number from, with the date we read it and the link status at that time.
| Document | Type | Retrieved | Link | Data points |
|---|---|---|---|---|
| Supporting patients through research collaboration Licence: See source | Press release | 16 Sep 2026 | Reachable | 9 |
| U.S. Medicine Use Trends 2026 Licence: See source | Press release | 15 Sep 2026 | Reachable | 25 |
| Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios Licence: See source | Press release | 15 Sep 2026 | Reachable | 17 |
| Global R&D Trends 2026 Licence: See source | Press release | 15 Sep 2026 | Reachable | 21 |
| Rethinking Clinical Trial Country Prioritization Licence: See source | Press release | 15 Sep 2026 | Reachable | 11 |
| Global R&D Trends 2026 Licence: See source | Press release | 15 Sep 2026 | Reachable | 20 |
| Global Oncology Trends 2025 Licence: See source | Press release | 16 Sep 2026 | Reachable | 27 |
| Global Medicine Use Trends 2026 Licence: See source | Press release | 15 Sep 2026 | Reachable | 12 |
| IQVIA Institute’s Global R&D Trends 2026 Report Finds Credible Signal on AI-Enabled Programs Licence: See source | Press release | 17 Sep 2026 | Reachable | 1 |
Measures from this publisher
Every measure taken from IQVIA, with its latest value and trend. Each value opens its record.
Market size and output 20
Oncology novel active substance (NAS) launches (cumulative) 132 +67% since 2015–2019 IQVIA 6 records
Show 14 more measures
- Novel active substance launches, five-year total 388
- Average annual revenue of patient organizations 12.5 billion USD
- Cell and gene therapy share of medicine spending 0.4%
- Cell and gene therapy spending 5.9 billion USD
- Cumulative cell and gene therapy launches 76
- Domestic-only oncology NAS launches (cumulative) 45
- Expected annual novel active substance launches (lower bound) 70
- Expected annual novel active substance launches (upper bound) 80
- Expected cumulative novel active substance launches (lower bound) 350
- Expected cumulative novel active substance launches (upper bound) 400
- Medicine spending 1.6 trillion USD
- Novel active substance launches (multi-year total) 270
- Novel active substance launches, five-year total (excluding COVID-19 products) 369
- Share of Pharmerging market pharmaceutical spending growth from top eight countries 83%
Prices and costs 3
Adoption and share 16
Large company small molecule share of Phase I clinical trial starts 66% +5 pp since 2022 IQVIA 4 records
Show 10 more measures
- Clinical trial country use share change -21%
- Non-retail share of medicine use 16%
- Novel modality share of oncology trials 35%
- Oncology share of all clinical trials 41%
- Phase I share of oncology trials 38%
- Phase II share of oncology trials 48%
- Phase III share of oncology trials 14%
- Rare cancer share of oncology trial starts 74%
- Retail share of medicine use 84%
- Share of patient organizations focused on rare diseases 18%
Growth and change 37
Show 31 more measures
- Phase II immunology clinical trial starts growth rate 14%
- Phase II oncology clinical trial starts growth rate 3%
- Phase III immunology clinical trial starts growth rate -4%
- Phase III oncology clinical trial starts growth rate 4%
- Annual revenue growth rate of largest patient organizations 5%
- Cell and gene therapy spending average annual growth rate 65%
- Cell and gene therapy spending growth rate 38%
- Cell and gene therapy spending year-over-year growth 38%
- Commercial insurance out-of-pocket cost growth 5%
- Commercial insurance out-of-pocket cost growth (5-year) 37%
- COVID-19 vaccines and therapeutics spending decline 4 billion USD
- Five-year cumulative medicine use growth 13%
- GIP/GLP-1 agonist spending growth contribution 14 billion USD
- High GDP developed countries medicine spending growth 155.1 billion constant USD
- Inter-trial interval increase 3 months
- Medicare out-of-pocket cost decline rate 2.2%
- Medicare out-of-pocket cost increase rate versus 2020 23%
- Medicare patient out-of-pocket medicine cost decline 638 million USD
- Medicine market average annual growth at net prices (5-year) 9.3%
- Medicine spending growth rate lower bound 5%
- Medicine spending growth rate upper bound 8%
- Net medicine spending increase 58 billion USD
- Obesity-approved GIP and GLP-1 agonist medicine spending growth 9.6 billion USD
- Oncology clinical development productivity growth 51%
- Oncology medicine spending growth (5-year) 75%
- Oncology medicine spending growth (annualized) 11.9%
- Patient out-of-pocket medicine cost increase 6 billion USD
- Prescription medicine use growth 1.5%
- Prescription medicine use growth (5-year) 13%
- Projected net medicine spending increase 200 billion USD
- Retail pharmacy prescription drug average annual growth (5-year) 2.4%
Other measures 13
Cell and gene therapy venture capital and public funding deal count 96 −1% since 2022 IQVIA 3 records
Show 7 more measures
- Medicine usage index 196 index
- Medicine use index (2020=100) 100 index
- Novel active substances launched exclusively in China 30
- Oncology clinical trial starts 2,162
- Patient organizations focused on rare diseases 593
- Patient organizations operating 3,327
- Prescription medicine use 210 billion days of therapy
89 measures. Each name opens the full series; each value opens the record with its source evidence.
Cite this page
Data on this page is published under CC BY 4.0. Credit IQVIA Institute as the original publisher; each record page carries its own citation.
IQVIA Institute. Retrieved from StatOrigin: https://statorigin.org/sources/iqvia-institute
Related
Industries using this source
- Pharmaceuticals 93
- Healthcare 79
Last verified 28 September 2026. Link status is rechecked weekly.